At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
sulindac +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma
In Brief
A Phase 2 clinical trial evaluating sulindac, placebo, and 1 other intervention for Precancerous Condition. Completed, enrolled 50 participants across 2 sites.
Detailed Summary
This randomized phase II trial is studying how well sulindac works in preventing melanoma in healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more effective than a placebo in preventing melanoma in individuals with many moles and abnormal moles.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrecancerous Condition
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedFeb 2009
Primary CompletionFeb 2011
TodayJul 2026
First PostedFeb 11, 2009
Enrollment StartFeb 1, 2009
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.4 years ago
Interventions
sulindacdrug
Given orally
placeboother
Inactive agent
laboratory biomarker analysisother
Correlative studies